Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma

NCT01863108 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Tumor Vaccines
Effects of Immunotherapy

Interventions

BIOLOGICAL: GeniusVac-Mel4

Sponsor

University Hospital, Grenoble

Collaborators

[object Object]
[object Object]
[object Object]